MARKET

HALO

HALO

Halozyme
NASDAQ

Real-time Quotes | Nasdaq Last Sale

40.29
-1.68
-4.00%
Closed 16:00 09/24 EDT
OPEN
41.62
PREV CLOSE
41.97
HIGH
41.69
LOW
40.27
VOLUME
715.82K
TURNOVER
--
52 WEEK HIGH
56.40
52 WEEK LOW
25.69
MARKET CAP
5.73B
P/E (TTM)
25.77
1D
5D
1M
3M
1Y
5Y
CIO names stocks that are resilient in the face of tax reform, pandemic and rising rates
Rob Luna from Surevest shares his top stock picks in the tech and bioscience sectors.
CNBC.com · 09/20 07:15
Halo Collective Today Announces the Completion of its At-the-Market Offering
Not for Distribution to U.S. Newswire Services or For Dissemination in the United States
CNW Group - CND · 09/17 21:05
Halo Collective's Bophelo Bioscience & Wellness Signs Distribution Agreement with Cantourage GmbH for Rapidly Growing European Market
COMTEX_393400375/2669/2021-09-15T16:10:29
CNW Group · 09/15 20:10
Halozyme to Participate in the 2021 Cantor Virtual Global Healthcare Conference
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Elaine Sun, senior vice president and chief financial officer, will present at the 2021 Cantor Virtual Global Healthcare Conference on Tuesday, September 28, 2021 at 1:20 p.m. Eastern Time / 1...
PR Newswire · 09/15 20:05
Halo Collective Announces Official Launch of Two Premium Cannabis Strains in Oregon with DNA Genetics
/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/
CNW Group - CND · 09/14 21:00
Halo Collective Acquires Pistil Point Indoor Facility
/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/All figures in USD, unless stated otherwise
CNW Group - CND · 09/13 20:15
/R E P E A T -- Halo Collective Begins Construction of Dispensary in Westwood, Los Angeles/
First of Three Southern California Locations Targeted to Open in Fourth Quarter 2021
CNW Group - CND · 09/13 13:00
Halozyme Therapeutics (HALO) Up 4.2% Since Last Earnings Report: Can It Continue?
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks · 09/08 15:30
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of HALO. Analyze the recent business situations of Halozyme through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 12 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average HALO stock price target is 52.82 with a high estimate of 66.00 and a low estimate of 17.00.
EPS
Institutional Holdings
Institutions: 431
Institutional Holdings: 147.28M
% Owned: 103.47%
Shares Outstanding: 142.33M
TypeInstitutionsShares
Increased
123
5.14M
New
27
598.01K
Decreased
108
5.58M
Sold Out
47
1.92M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.13%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Chairman/Independent Director
Connie Matsui
President/Chief Executive Officer/Director
Helen Torley
Chief Financial Officer/Senior Vice President
Elaine Sun
Senior Vice President/Chief Technology Officer
Michael LaBarre
Senior Vice President/Chief Compliance Officer/General Counsel/Secretary
Masaru Matsuda
Independent Director
Jean-Pierre Bizzari
Independent Director
Bernadette Connaughton
Independent Director
James Daly
Independent Director
Jeffrey Henderson
Independent Director
Matthew Posard
No Data
  • All
  • Financials
  • Insiders
More
About HALO
Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company's segment also includes research and development activities and product sales of Hylenex recombinant. The Company's development pipeline consists of clinical-stage product candidates in oncology. Its lead oncology program is PEGPH20 (polyethylene glycol (PEG)ylated recombinant human hyaluronidase), a molecular entity being developed for the systemic treatment of tumors, which accumulate HA. It is in Phase II and Phase III clinical testing for PEGPH20 in stage IV pancreatic ductal adenocarcinoma (Studies 109-202 and 109-301); Phase Ib clinical testing in non-small cell lung cancer (Study 107-201), and in Phase Ib clinical testing in non-small cell lung cancer and gastric cancer (Study 107-101).

Webull offers kinds of Halozyme Therapeutics, Inc. stock information, including NASDAQ:HALO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HALO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading HALO stock methods without spending real money on the virtual paper trading platform.